中国中西医结合杂志
中國中西醫結閤雜誌
중국중서의결합잡지
CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2001年
5期
328-331
,共4页
徐振晔%朱晏伟%周卫东%张晖%鞠艳芳%赵丽红%邓海滨%吴继%沈德义%张蕙心
徐振曄%硃晏偉%週衛東%張暉%鞠豔芳%趙麗紅%鄧海濱%吳繼%瀋德義%張蕙心
서진엽%주안위%주위동%장휘%국염방%조려홍%산해빈%오계%침덕의%장혜심
双黄升白冲剂%化疗骨髓抑制%升白细胞%骨髓微环境
雙黃升白遲劑%化療骨髓抑製%升白細胞%骨髓微環境
쌍황승백충제%화료골수억제%승백세포%골수미배경
目的：观察中药双黄升白冲剂对肿瘤化疗患者的升白疗效及对小鼠骨髓造血微环境的作用。方法：选择主要为复治的非小细胞肺癌及乳腺癌、胃癌、肠癌患者，随机分为4组。治疗1组(28例)为化疗同时服用双黄升白冲剂；治疗2组(27例)为WBC＜4×109／L始用双黄升白冲剂；对照1组(33例)为化疗同时服用茜草双酯；对照2组(24例)为WBC＜4×109／L始用茜草双酯。并做实验研究电镜观察小鼠骨髓超微结构。结果：升白疗效总有效率治疗1组为75.00%，治疗2组为88.89%；对照1组为54.55%，对照2组为58.33%。治疗组与对照组比较差异有显著性(P＜0.01)。双黄升白冲剂对小鼠骨髓有良好的保护、改善造血微环境的作用。结论：中药双黄升白冲剂对化疗后骨髓受抑制肿瘤患者具有明显的保护和治疗作用。
目的：觀察中藥雙黃升白遲劑對腫瘤化療患者的升白療效及對小鼠骨髓造血微環境的作用。方法：選擇主要為複治的非小細胞肺癌及乳腺癌、胃癌、腸癌患者，隨機分為4組。治療1組(28例)為化療同時服用雙黃升白遲劑；治療2組(27例)為WBC＜4×109／L始用雙黃升白遲劑；對照1組(33例)為化療同時服用茜草雙酯；對照2組(24例)為WBC＜4×109／L始用茜草雙酯。併做實驗研究電鏡觀察小鼠骨髓超微結構。結果：升白療效總有效率治療1組為75.00%，治療2組為88.89%；對照1組為54.55%，對照2組為58.33%。治療組與對照組比較差異有顯著性(P＜0.01)。雙黃升白遲劑對小鼠骨髓有良好的保護、改善造血微環境的作用。結論：中藥雙黃升白遲劑對化療後骨髓受抑製腫瘤患者具有明顯的保護和治療作用。
목적：관찰중약쌍황승백충제대종류화료환자적승백료효급대소서골수조혈미배경적작용。방법：선택주요위복치적비소세포폐암급유선암、위암、장암환자，수궤분위4조。치료1조(28례)위화료동시복용쌍황승백충제；치료2조(27례)위WBC＜4×109／L시용쌍황승백충제；대조1조(33례)위화료동시복용천초쌍지；대조2조(24례)위WBC＜4×109／L시용천초쌍지。병주실험연구전경관찰소서골수초미결구。결과：승백료효총유효솔치료1조위75.00%，치료2조위88.89%；대조1조위54.55%，대조2조위58.33%。치료조여대조조비교차이유현저성(P＜0.01)。쌍황승백충제대소서골수유량호적보호、개선조혈미배경적작용。결론：중약쌍황승백충제대화료후골수수억제종류환자구유명현적보호화치료작용。
Objective: To observe the leukocyte increasing effects ofShuanghuang Shengbai Granule (SHSBG) in tumor patients treated by chemotherapy (CT) and its function on bone marrow hematopoietic microenvironment in mice. Methods: Patients of non-small-cell lung cancer and breast, gastric or intestinal cancer, who were retreated with CT, were enrolled and divided into 4 groups randomly. The 28 cases in the treated group 1 received SHSBG and CT simultaneously. The 27 cases in the treated group 2 also received firstly CT, and SHSBG started when WBC count lowered to less than 4×109／L after CT. The control group 1 and 2 (n＝33 and n＝24) was treated by the method similar to that applied to the treated group 1 and 2 respectively but with Rubidate instead of SHSBG. Experimental study of observing bone marrow ultrastructure in mice was also conducted with electron microscopy. Results: The total leukocyte increasing effective rate occurred in the treated group 1 was 75.00%, that in the treated group 2 was 88.89%, in the control group 1 was 54.55% and in the control group 2 was 58.33%. There was significant difference between the treated groups and the control groups (P＜0.01). Experimental study showed that SHSBG has good bone marrow hematopoietic microenvironment protecting and improving effect in mice. Conclusion: SHSBG has obvious protecting and treating effect on CT caused bone marrow suppression in tumor patients.
